• Allergan, Inc. and Medytox v. Daewoong Pharm and Evolus (Int’l Trade Comm’n 2020) – dispute over genetic origin of C. Botulinum toxin strain and process parameters used to manufacture botulinum neurotoxin product
  • Takeda, Millennium Pharm. v. Genentech, Inc. (Del. Ch. 2018) – licensing dispute over patents claiming the use of monoclonal antibodies with high levels of fucose in order to decrease ADCC activity and corresponding levels of inflammation
  • Juno Therapeutics & Memorial Sloan Kettering v. Kite Pharma (C.D. Cal. 2017) – biologic patent litigation involving chimeric antigen receptor technology (CAR-T) for T-cells targeting CD19 and FDA's first approved CAR-T, axicabtagene ciloleucel (YESCARTA™), for the treatment of non-Hodgkin lymphoma
  • Depomed v. Actavis, Roxane & Alkem (Fed. Cir. 2017; D.N.J. 2016) — ANDA litigation against generic applicants for various dosage forms of tapentadol hydrochloride (NUCYNTA®) for the treatment of polyneuropathic pain and diabetic peripheral neuropathy
  • Shire Pharm. v. Ultragenyx Pharm. (D.Mass. 2017) – trade secret litigation involving the ultra-rare disease mucopolysaccharidosis VII (MPS VII) and its first treatment, MEPSEVII
  • Oakwood Labs v. Aurobindo Pharma. (D.N.J. 2017) – trade secret litigation involving formulation of peptide-based microspheres encapsulating leuprolide and octreotide for injectable devices
  • Takeda v. Burwell (D.D.C. 2014; D.C. Cir. 2016) – challenging FDA's improper approval of 505(b)(2) generic colchicine drug (Colcrys®) without requiring patent certification to method of use patents
  • Almha v. Allergan (D. Kan. 2013) – defense of patent infringement allegations concerning structural elements of an improved inframammary breast prosthesis
  • Medicis v. GlaxoSmithKline & Stiefel (W.D. Tex. 2012, D.N.J. 2012) – patent litigation against 505(b)(2) competitor using the patented formulation for Ziana® product
  • Medicis v. Actavis (D. Del. 2012) – ANDA litigation against generic applicant for drug combination clindamycin phosphate/tretinoin topical gel for dermatological applications
  • Novo Nordisk v. Caraco Labs & Sun Pharm. (S.Ct. 2011; Fed. Cir. 2010; E.D. Mich. 2009) – litigation and appeals concerning the change in use code narrative associated with Novo Nordisk's Prandin®
  • Novo Nordisk v. Caraco, Sun, Mylan, Paddock, Sandoz & Aurobindo, (Fed. Cir. 2012; E.D. Mich. 2011 & 2012; D.N.J. 2009; D. Minn. 2011) – ANDA litigation against generic applicants for repaglinide (PRANDIN®) for the treatment of Type 2 diabetes when used in combination with metformin
  • Novo Nordisk v. Actavis, Sandoz & Lupin (S.D.N.Y. 2011) – ANDA litigation against generic applicants for the single dose combination product repaglinide/metformin (Prandimet®) for the treatment of Type 2 diabetes
  • Isis Pharmaceutical v. Santaris Pharma A/S (S.D. Cal. 2012) – defense of patent infringement allegations arising out of the development of antisense oligonucleotides (LNAs) for the treatment of various diseases and medical conditions
  • Biogen IDEC MA v. Merck Serono (D.N.J. 2011) – defense of patent infringement allegations arising out of the production of interferon-β in CHO cells under the biologics license granted by FDA
  • In re: Ditropan Litigation (N.D. Cal. 2008) – defense of antitrust claims arising out of ANDA litigation concerning generic oxybutynin for the treatment of urological disorders
  • Thoratec v. Bodycote – defense of patent infringement allegations concerning a biocompatible coating used in cardiovascular implantable devices
  • C.R. Bard v. AHI Cardiovascular Surgeons, Inc. (D. Ariz.) – patent litigation arising out of inventorship and ownership claims to original patented stent technology
  • Impra, Inc. v. Endomed (D. Ariz.) – defense of patent infringement and trade secret misappropriation allegations arising out of the design of polytetraflouroetheylene (PTFE) vascular grafts